PRKCB and B-cell chronic lymphocytic leukemia: Enzastaurin (LY317615), a small-molecule inhibitor targeted towards PI3K/PKCβ pathways, has been demonstrated to induce apoptosis in CLL cells in vitro [38,42]; however, there is limited published data available from clinical trials in CLL patients.